Clinical trial · Observational
Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma
NCT07703735CI-TRIAL-00117822HCCenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Liver Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival, Recurrence-free Survival
- timeFrame
- Up to 10 years after transplantation
- description
- Time from liver transplantation until death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:• Adult patients (≥18 years) * Underwent living donor liver transplantation for HCC * Transplantation between Jan 2012 - Dec 2023 Exclusion Criteria: * • Deceased donor liver transplantation * Re-transplantation
References
Publications (0)
Data not yet available
No reference posted for this study.